ReNAgade Therapeutics CEO Amit Munshi (L) and Orna Therapeutics CEO Tom Barnes
ReNAgade is acquired by RNA rival a year after megaround-backed launch
Two buzzy, well-funded biotech startups are combining in a bid to create a powerhouse at the bleeding edge of genetic medicines.
Orna Therapeutics announced Thursday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.